Irish Study Finds Cystic Fibrosis Drug Safe for Newborns
An RCSI and Children's Health Ireland study has shown that Ivacaftor is safe for treating newborns with cystic fibrosis from four weeks old.
Silicon Republic 2:15 pm on April 11, 2024
Scientists at the Royal College of Surgeons Ireland (RCSI) have conducted a study, finding Ivacaftor safe for treating cystic fibrosis in newborns. Ivacaftor, also known as Kalydek, is already used in adults and older children but this marks the first time it has been proven effective and safe in infants as young as four weeks old. This development will provide hope and reassurance to families of newly diagnosed cystic fibrosis patients. The drug targets the underlying defect that causes cystic fibrosis, an inherited condition affecting mainly the lungs and digestive system.
- RCSI study proves Ivacaftor safe for newborns with cystic fibrosis
- Drug, already used in adults and children, targets underlying defect of CF
- Available treatment for newly diagnosed infants will bring hope to families
- Effective in treating cystic fibrosis, an inherited condition mainly affecting lungs and digestive system
- First proven safe for use in infants as young as four weeks old
https://www.siliconrepublic.com/innovation/cystic-fibrosis-treatment-rcsi-study-ivacaftor